OMERS ADMINISTRATION Corp Invests $1.06 Million in Krystal Biotech, Inc. $KRYS

OMERS ADMINISTRATION Corp acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 1st quarter, HoldingsChannel reports. The institutional investor acquired 4,100 shares of the company’s stock, valued at approximately $1,059,000.

A number of other institutional investors have also recently bought and sold shares of KRYS. Handelsbanken Fonder AB lifted its stake in Krystal Biotech by 58.4% in the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock valued at $26,084,000 after purchasing an additional 39,000 shares during the last quarter. SG Americas Securities LLC increased its position in Krystal Biotech by 469.9% in the fourth quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock worth $4,662,000 after buying an additional 15,591 shares during the last quarter. Fisher Asset Management LLC bought a new stake in shares of Krystal Biotech in the fourth quarter valued at $933,000. Principal Financial Group Inc. raised its stake in shares of Krystal Biotech by 15.6% in the fourth quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock valued at $40,697,000 after buying an additional 22,231 shares during the period. Finally, Biondo Investment Advisors LLC lifted its position in shares of Krystal Biotech by 31.3% during the 4th quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock valued at $16,797,000 after buying an additional 16,245 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Price Performance

KRYS opened at $366.85 on Friday. The firm has a market capitalization of $10.81 billion, a P/E ratio of 49.04 and a beta of 0.50. Krystal Biotech, Inc. has a one year low of $130.50 and a one year high of $382.54. The company has a fifty day moving average price of $338.86 and a 200-day moving average price of $295.96.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The company had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. On average, analysts expect that Krystal Biotech, Inc. will post 7.31 earnings per share for the current year.

Insider Activity

In other news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 26,642 shares of company stock worth $8,243,923. Insiders own 13.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on KRYS. Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Citigroup boosted their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a report on Monday, July 13th. Finally, HC Wainwright lifted their price target on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research report on Tuesday, June 16th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $360.67.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.